AZN - AstraZeneca PLC

NYSE - NYSE Delayed Price. Currency in USD
35.29
+0.17 (+0.48%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close35.12
Open35.18
Bid35.31 x 2100
Ask35.35 x 3700
Day's Range34.89 - 35.37
52 Week Range28.43 - 36.75
Volume3,351,201
Avg. Volume4,318,524
Market Cap85.956B
Beta0.57
PE Ratio (TTM)29.78
EPS (TTM)1.18
Earnings DateN/A
Forward Dividend & Yield1.40 (3.92%)
Ex-Dividend Date2018-02-15
1y Target Est38.89
Trade prices are not sourced from all markets
  • NEWS BITES: Barbara Bush dies at 92, Sessions proposes new limits on opioid production, tax day extended
    Yahoo Finance Video8 days ago

    NEWS BITES: Barbara Bush dies at 92, Sessions proposes new limits on opioid production, tax day extended

    Here’s a quick wrap up of other headlines making news today.

  • Analysts’ Estimates for Sanofi’s 1Q18 Earnings
    Market Realist17 hours ago

    Analysts’ Estimates for Sanofi’s 1Q18 Earnings

    Paris-headquartered Sanofi (SNY), one of the world’s largest pharmaceutical companies, reports its financial results in euros. The company is set to release its 1Q18 earnings on April 27. Analysts expect Sanofi to report EPS (earnings per share) of 1.13 euros and revenue of 8.1 billion euros.

  • Ozempic Could Be Potential Driver for Novo Nordisk in 2018
    Market Realistyesterday

    Ozempic Could Be Potential Driver for Novo Nordisk in 2018

    In December 2017, the FDA approved Novo Nordisk’s (NVO) Ozempic as an add-on to diet and exercise for the management of blood sugar levels in adult individuals with Type 2 diabetes.

  • Reuters2 days ago

    AstraZeneca raises stake in respiratory partner Circassia

    By Paul Sandle LONDON (Reuters) - AstraZeneca (AZN.L) is paying up to $45 million (32.25 million pounds) to increase its stake in Circassia (CIRCI.L), backing a company seeking to bounce back from the ...

  • Reuters2 days ago

    AstraZeneca flop a fresh blow to cancer immunotherapy combination

    The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca clinical study. Adding the company's experimental drug tremelimumab to its existing product Imfinzi failed to slow disease progression or extend life in patients who had already received at least two previous treatments, the drugmaker said on Tuesday.

  • Investopedia2 days ago

    AstraZeneca’s Lung Cancer Duo Flops

    AstraZeneca’s combo of the experimental drug tremelimumab and Imfinzi failed to slow disease progression or extend life for lung cancer patients

  • Reuters2 days ago

    AstraZeneca third-line lung cancer combination study fails

    A combination of AstraZeneca immunotherapy drugs in lung cancer patients who have already received at least two previous treatments has failed to show a benefit in slowing disease progression or helping ...

  • Analysts’ Recommendations for Eli Lilly & Co. on April 20
    Market Realist3 days ago

    Analysts’ Recommendations for Eli Lilly & Co. on April 20

    Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 4Q17. The company reported EPS of $1.14 on revenues of ~$6.2 billion, compared to the estimated EPS of $1.07 on revenues of ~$5.9 billion. Analysts expect the company to report EPS of $1.14 on revenues of $5.5 billion during 1Q18.

  • FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)
    Zacks3 days ago

    FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC (revised)

    Tagrisso is approved in the United States, European Union, Japan and China as second-line treatment for patients with advanced NSCLC.

  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks6 days ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC
    Zacks7 days ago

    FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC

    AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.

  • Reuters7 days ago

    AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug

    U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday. The latest Food and Drug Administration approval includes patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.

  • Analysts’ Recommendations for Novartis on April 17
    Market Realist8 days ago

    Analysts’ Recommendations for Novartis on April 17

    Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.

  • Novartis’s 1Q18 Estimates: Expectations for Alcon
    Market Realist8 days ago

    Novartis’s 1Q18 Estimates: Expectations for Alcon

    Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. Alcon products are marketed in over 180 countries worldwide. Alcon is expected to report growth in revenue following increased demand for contact lenses and surgical products in 1Q18.

  • American City Business Journals9 days ago

    A new Highmark contract with a pharma company part of a growing trend in drug purchasing

    If a certain drug doesn't work to manufacturers' expectations, then the insurer either doesn't pay for it or gets a rebate.

  • Updates on AbbVie’s AndroGel, Lupron, and Kaletra
    Market Realist9 days ago

    Updates on AbbVie’s AndroGel, Lupron, and Kaletra

    In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter. In fiscal 2017, AndroGel generated revenue of $577 million, marking a ~14.5% decline YoY.

  • An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Shows It’s 34% Undervalued
    Simply Wall St.9 days ago

    An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Shows It’s 34% Undervalued

    How far off is AstraZeneca PLC (LSE:AZN) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...

  • Business Wire10 days ago

    Updated Overall Survival Data for LYNPARZA® (olaparib) in gBRCA-Mutated HER2-Negative Metastatic Breast Cancer Presented at AACR

    AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today presented data from the Phase III OlympiAD trial, showing the final overall survival results for LYNPARZA® in metastatic breast cancer at the American Association for Cancer Research Annual Meeting in Chicago, April 14-18, 2018.

  • Barclays Downgrades Pfizer Stock and Cuts Price Target
    Market Realist15 days ago

    Barclays Downgrades Pfizer Stock and Cuts Price Target

    On April 5, 2018, Barclays (BCS) updated its recommendations for some leading US pharmaceutical companies. It downgraded its recommendation for Pfizer (PFE) from “overweight” to “equal weight,” and Barclays analyst Geoff Meacham cut his price target on Pfizer stock from $41 to $38. That day, Pfizer stock fell ~1.3% following the announcement of the rating downgrade. 

  • Spectrum Pharma Stock Up on Positive Lung Cancer Study Data
    Zacks15 days ago

    Spectrum Pharma Stock Up on Positive Lung Cancer Study Data

    Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.

  • What Boosted Merck’s Stock Price on April 9
    Market Realist15 days ago

    What Boosted Merck’s Stock Price on April 9

    On April 9, 2018, Merck (MRK) stock rose ~4.4% in early trading and ~2.7% during the day. The highest price reached on April 9 was 7% higher than the stock’s April 8 closing price. Peers Bristol-Myers Squibb (BMY), AstraZeneca (AZN), and Roche (ROG) returned -0.08%, 0.24%, and 0.05%, respectively on April 9, and the SPDR S&P 500 ETF (SPY) rose ~1.1%. MRK accounts for ~0.65% of SPY’s total holdings.

  • How GlaxoSmithKline Stock Performed in 1Q18
    Market Realist15 days ago

    How GlaxoSmithKline Stock Performed in 1Q18

    GlaxoSmithKline (GSK) is a British multinational pharmaceutical company with headquarters in Brentford, Middlesex. The company classifies its business portfolio into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

  • Ionis (IONS) Clinches Licensing Agreement with AstraZeneca
    Zacks16 days ago

    Ionis (IONS) Clinches Licensing Agreement with AstraZeneca

    Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.

  • How AstraZeneca’s 1Q18 Shook Out
    Market Realist16 days ago

    How AstraZeneca’s 1Q18 Shook Out

    Headquartered in London, AstraZeneca (AZN) is a pharmaceutical company with operations in over 100 countries. The company is involved in the research, development, and manufacture of drugs for both primary care and specialty care.

  • Top Analyst Reports for Microsoft, Merck & Union Pacific
    Zacks16 days ago

    Top Analyst Reports for Microsoft, Merck & Union Pacific

    Top Analyst Reports for Microsoft, Merck & Union Pacific